Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Allogeneic hematopoietic cell transplantation from alternative sources for adult Philadelphia chromosome-negative ALL: what should we choose when no HLA-matched related donor is available?

Bone Marrow Transplantation volume 48, pages 1369–1376 (2013)Cite this article

Subjects

Abstract

The best outcome for patients with Ph chromosome-negative ALL (Ph(−) ALL) can be obtained by HLA-matched related donor (mRD) allogeneic hematopoietic cell transplantation (allo-HCT) in first CR. However, only 30% of patients have a mRD. Three alternative sources, unrelated donor (URD), cord blood, and haploidentical related donor (haplo-RD), are available. URD allo-HCT is an old-established alternative source, and recent data have shown that URD allo-HCT can result in OS comparable with that with mRD allo-HCT for patients with Ph(−) ALL in first CR (OS at 4 years: mRD 65% vs URD 62%). Unrelated cord blood transplantation can also be indicated for patients with Ph(−) ALL in first CR (OS at 4 years: 57%), especially for young patients without an HLA-matched URD or patients who are in urgent need for allo-HCT. Limited data for haplo-RD allo-HCT for ALL showed utility in CR (OS at 3 years: up to 65%) but a survival rate of only 5–7% in non-CR. As there are no confirmed data about the utility of allo-HCT from an alternative source for adolescent and young adults who are eligible for pediatric protocols or for elderly patients with reduced-intensity conditioning. Further investigation, including investigation of minimal residual disease detection, may reveal subgroups of patients who can receive benefits from allo-HCT. Selection of the best source based on the patient status and appropriate timing is warranted.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Rowe JM, Buck G, Burnett AK, Chopra R, Wiernik PH, Richards SM et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood 2005; 106: 3760–3767.

    Article  CAS  PubMed  Google Scholar 

  2. Kantarjian H, Thomas D, O'Brien S, Cortes J, Giles F, Jeha S et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer 2004; 101: 2788–2801.

    Article  CAS  PubMed  Google Scholar 

  3. Gokbuget N, Hoelzer D, Arnold R, Bohme A, Bartram CR, Freund M et al. Treatment of adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL). Hematol Oncol Clin North Am 2000; 14: 1307–1325 ix.

    Article  CAS  PubMed  Google Scholar 

  4. Larson RA, Dodge RK, Burns CP, Lee EJ, Stone RM, Schulman P et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood 1995; 85: 2025–2037.

    CAS  PubMed  Google Scholar 

  5. Linker C, Damon L, Ries C, Navarro W . Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia. J Clin Oncol 2002; 20: 2464–2471.

    Article  CAS  PubMed  Google Scholar 

  6. Annino L, Vegna ML, Camera A, Specchia G, Visani G, Fioritoni G et al. Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood 2002; 99: 863–871.

    Article  CAS  PubMed  Google Scholar 

  7. Thomas X, Boiron JM, Huguet F, Dombret H, Bradstock K, Vey N et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol 2004; 22: 4075–4086.

    Article  CAS  PubMed  Google Scholar 

  8. Takeuchi J, Kyo T, Naito K, Sao H, Takahashi M, Miyawaki S et al. Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93 study. Leukemia 2002; 16: 1259–1266.

    Article  CAS  PubMed  Google Scholar 

  9. Ballen KK, Koreth J, Chen YB, Dey BR, Spitzer TR . Selection of optimal alternative graft source: mismatched unrelated donor, umbilical cord blood, or haploidentical transplant. Blood 2012; 119: 1972–1980.

    Article  CAS  PubMed  Google Scholar 

  10. Ballen KK, Spitzer TR . The great debate: haploidentical or cord blood transplant. Bone Marrow Transplant 2011; 46: 323–329.

    Article  CAS  PubMed  Google Scholar 

  11. Aversa F . Haploidentical haematopoietic stem cell transplantation for acute leukaemia in adults: experience in Europe and the United States. Bone Marrow Transplant 2008; 41: 473–481.

    Article  CAS  PubMed  Google Scholar 

  12. Nishiwaki S, Inamoto Y, Imamura M, Tsurumi H, Hatanaka K, Kawa K et al. Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in complete remission. Blood 2011; 117: 3698–3699.

    Article  CAS  PubMed  Google Scholar 

  13. Holowiecki J, Krawczyk Kulis M, Giebel S, Jagoda K, Stella Holowiecka B, Piatkowska Jakubas B et al. Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4-2002 MRD Study. Br J Haematol 2008; 142: 227–237.

    Article  PubMed  Google Scholar 

  14. Bassan R, Spinelli O, Oldani E, Intermesoli T, Tosi M, Peruta B et al. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood 2009; 113: 4153–4162.

    Article  CAS  PubMed  Google Scholar 

  15. Bruggemann M, Schrauder A, Raff T, Pfeifer H, Dworzak M, Ottmann OG et al. Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18–20 September 2008. Leukemia 2010; 24: 521–535.

    Article  CAS  PubMed  Google Scholar 

  16. Campana D . Minimal residual disease in acute lymphoblastic leukemia. Hematology (Am Soc Hematol Educ Program) 2010; 2010: 7–12.

    Article  Google Scholar 

  17. Patel B, Rai L, Buck G, Richards SM, Mortuza Y, Mitchell W et al. Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993. Br J Haematol 2010; 148: 80–89.

    Article  CAS  PubMed  Google Scholar 

  18. Garand R, Beldjord K, Cave H, Fossat C, Arnoux I, Asnafi V et al. Flow cytometry and IG/TCR quantitative PCR for minimal residual disease quantitation in acute lymphoblastic leukemia: a French multicenter prospective study on behalf of the FRALLE, EORTC and GRAALL. Leukemia 2012; 27: 370–376.

    Article  PubMed  Google Scholar 

  19. Tavernier E, Boiron JM, Huguet F, Bradstock K, Vey N, Kovacsovics T et al. Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial. Leukemia 2007; 21: 1907–1914.

    Article  CAS  PubMed  Google Scholar 

  20. Fielding AK, Richards SM, Chopra R, Lazarus HM, Litzow MR, Buck G et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood 2007; 109: 944–950.

    Article  CAS  PubMed  Google Scholar 

  21. Oriol A, Vives S, Hernandez Rivas JM, Tormo M, Heras I, Rivas C et al. Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group. Haematologica 2010; 95: 589–596.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Goldstone AH, Richards SM, Lazarus HM, Tallman MS, Buck G, Fielding AK et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood 2008; 111: 1827–1833.

    Article  CAS  PubMed  Google Scholar 

  23. Nishiwaki S, Inamoto Y, Sakamaki H, Kurokawa M, Iida H, Ogawa H et al. Allogeneic stem cell transplantation for adult Philadelphia chromosome-negative acute lymphocytic leukemia: comparable survival rates but different risk factors between related and unrelated transplantation in first complete remission. Blood 2010; 116: 4368–4375.

    Article  CAS  PubMed  Google Scholar 

  24. Kako S, Morita S, Sakamaki H, Ogawa H, Fukuda T, Takahashi S et al. A decision analysis of allogeneic hematopoietic stem cell transplantation in adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission who have an HLA-matched sibling donor. Leukemia 2011; 25: 259–265.

    Article  CAS  PubMed  Google Scholar 

  25. Marks DI, Perez WS, He W, Zhang MJ, Bishop MR, Bolwell BJ et al. Unrelated donor transplants in adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission. Blood 2008; 112: 426–434.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Oh H, Loberiza FR, Zhang MJ, Ringden O, Akiyama H, Asai T et al. Comparison of graft-versus-host-disease and survival after HLA-identical sibling bone marrow transplantation in ethnic populations. Blood 2005; 105: 1408–1416.

    Article  CAS  PubMed  Google Scholar 

  27. Baker KS, Loberiza FR, Yu H, Cairo MS, Bolwell BJ, Bujan-Boza WA et al. Outcome of ethnic minorities with acute or chronic leukemia treated with hematopoietic stem-cell transplantation in the United States. J Clin Oncol 2005; 23: 7032–7042.

    Article  PubMed  Google Scholar 

  28. Mehta J . Hematopoietic stem cell transplantation from unrelated donors for acute leukemia. Blood 2008; 112: 447–448.

    Article  CAS  PubMed  Google Scholar 

  29. Kanda J, Saji H, Fukuda T, Kobayashi T, Miyamura K, Eto T et al. Related transplantation with HLA-1 Ag mismatch in the GVH direction and HLA-8/8 allele-matched unrelated transplantation: a nationwide retrospective study. Blood 2012; 119: 2409–2416.

    Article  CAS  PubMed  Google Scholar 

  30. Nishiwaki S, Miyamura K, Ohashi K, Kurokawa M, Taniguchi S, Fukuda T et al. Impact of a donor source on adult Philadelphia chromosome-negative acute lymphoblastic leukemia: a retrospective analysis from the Adult Acute Lymphoblastic Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation. Ann Oncol, (e-pub ahead of print 31 January 2013; doi:10.1093/annonc/mds655).

  31. Atsuta Y, Suzuki R, Nagamura-Inoue T, Taniguchi S, Takahashi S, Kai S et al. Disease-specific analyses of unrelated cord blood transplantation compared with unrelated bone marrow transplantation in adult patients with acute leukemia. Blood 2009; 113: 1631–1638.

    Article  PubMed  Google Scholar 

  32. Tomblyn MB, Arora M, Baker KS, Blazar BR, Brunstein CG, Burns LJ et al. Myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia: analysis of graft sources and long-term outcome. J Clin Oncol 2009; 27: 3634–3641.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Zhang H, Chen J, Que W . A meta-analysis of unrelated donor umbilical cord blood transplantation versus unrelated donor bone marrow transplantation in acute leukemia patients. Biol Blood Marrow Transplant 2012; 18: 1164–1173.

    Article  PubMed  Google Scholar 

  34. Atsuta Y, Morishima Y, Suzuki R, Nagamura-Inoue T, Taniguchi S, Takahashi S et al. Comparison of unrelated cord blood transplantation and HLA-mismatched unrelated bone marrow transplantation for adults with leukemia. Biol Blood Marrow Transplant 2012; 18: 780–787.

    Article  PubMed  Google Scholar 

  35. Kanda J, Atsuta Y, Wake A, Ichinohe T, Takanashi M, Morishima Y et al. Impact of the direction of HLA mismatch on transplant outcome in single unrelated cord blood transplantation. Biol Blood Marrow Transplant 2013; 19: 247–254.

    Article  PubMed  Google Scholar 

  36. Aversa F, Terenzi A, Tabilio A, Falzetti F, Carotti A, Ballanti S et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 2005; 23: 3447–3454.

    Article  PubMed  Google Scholar 

  37. Ciceri F, Labopin M, Aversa F, Rowe JM, Bunjes D, Lewalle P et al. A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation. Blood 2008; 112: 3574–3581.

    Article  CAS  PubMed  Google Scholar 

  38. Munchel AT, Kasamon YL, Fuchs EJ . Treatment of hematological malignancies with nonmyeloablative, HLA-haploidentical bone marrow transplantation and high dose, post-transplantation cyclophosphamide. Best Pract Res Clin Haematol 2011; 24: 359–368.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W et al. Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation. Biol Blood Marrow Transplant 2009; 15: 257–265.

    Article  CAS  PubMed  Google Scholar 

  40. Marks DI, Aversa F, Lazarus HM . Alternative donor transplants for adult acute lymphoblastic leukaemia: a comparison of the three major options. Bone Marrow Transplant 2006; 38: 467–475.

    Article  CAS  PubMed  Google Scholar 

  41. Brunstein CG, Fuchs EJ, Carter SL, Karanes C, Costa LJ, Wu J et al. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood 2011; 118: 282–288.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Laughlin MJ, Eapen M, Rubinstein P, Wagner JE, Zhang MJ, Champlin RE et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med 2004; 351: 2265–2275.

    Article  CAS  PubMed  Google Scholar 

  43. Rocha V, Labopin M, Sanz G, Arcese W, Schwerdtfeger R, Bosi A et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med 2004; 351: 2276–2285.

    Article  CAS  PubMed  Google Scholar 

  44. Takahashi S, Iseki T, Ooi J, Tomonari A, Takasugi K, Shimohakamada Y et al. Single-institute comparative analysis of unrelated bone marrow transplantation and cord blood transplantation for adult patients with hematologic malignancies. Blood 2004; 104: 3813–3820.

    Article  CAS  PubMed  Google Scholar 

  45. Barker JN, Weisdorf DJ, DeFor TE, Blazar BR, McGlave PB, Miller JS et al. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood 2005; 105: 1343–1347.

    Article  CAS  PubMed  Google Scholar 

  46. Rocha V, Crotta A, Ruggeri A, Purtill D, Boudjedir K, Herr AL et al. Double cord blood transplantation: extending the use of unrelated umbilical cord blood cells for patients with hematological diseases. Best Pract Res Clin Haematol 2010; 23: 223–229.

    Article  PubMed  Google Scholar 

  47. Brunstein CG, Gutman JA, Weisdorf DJ, Woolfrey AE, Defor TE, Gooley TA et al. Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood. Blood 2010; 116: 4693–4699.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Frassoni F, Gualandi F, Podesta M, Raiola AM, Ibatici A, Piaggio G et al. Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a phase I/II study. Lancet Oncol 2008; 9: 831–839.

    Article  CAS  PubMed  Google Scholar 

  49. Brunstein CG, Barker JN, Weisdorf DJ, Defor TE, McKenna D, Chong SY et al. Intra-BM injection to enhance engraftment after myeloablative umbilical cord blood transplantation with two partially HLA-matched units. Bone Marrow Transplant 2009; 43: 935–940.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Frassoni F, Varaldo R, Gualandi F, Bacigalupo A, Sambuceti G, Sacchi N et al. The intra-bone marrow injection of cord blood cells extends the possibility of transplantation to the majority of patients with malignant hematopoietic diseases. Best Pract Res Clin Haematol 2010; 23: 237–244.

    Article  PubMed  Google Scholar 

  51. Delaney C, Heimfeld S, Brashem-Stein C, Voorhies H, Manger RL, Bernstein ID . Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution. Nat Med 2010; 16: 232–236.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Kelly SS, Sola CB, de Lima M, Shpall E . Ex vivo expansion of cord blood. Bone Marrow Transplant 2009; 44: 673–681.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Ooi J, Takahashi S, Tomonari A, Tsukada N, Konuma T, Kato S et al. Unrelated cord blood transplantation after myeloablative conditioning in adults with acute myelogenous leukemia. Biol Blood Marrow Transplant 2008; 14: 1341–1347.

    Article  CAS  PubMed  Google Scholar 

  54. Ooi J, Iseki T, Takahashi S, Tomonari A, Takasugi K, Shimohakamada Y et al. Unrelated cord blood transplantation for adult patients with de novo acute myeloid leukemia. Blood 2004; 103: 489–491.

    Article  CAS  PubMed  Google Scholar 

  55. Sanz J, Sanz MA, Saavedra S, Lorenzo I, Montesinos P, Senent L et al. Cord blood transplantation from unrelated donors in adults with high-risk acute myeloid leukemia. Biol Blood Marrow Transplant 2010; 16: 86–94.

    Article  PubMed  Google Scholar 

  56. Ooi J, Iseki T, Takahashi S, Tomonari A, Ishii K, Takasugi K et al. Unrelated cord blood transplantation for adult patients with advanced myelodysplastic syndrome. Blood 2003; 101: 4711–4713.

    Article  CAS  PubMed  Google Scholar 

  57. Sato A, Ooi J, Takahashi S, Tsukada N, Kato S, Kawakita T et al. Unrelated cord blood transplantation after myeloablative conditioning in adults with advanced myelodysplastic syndromes. Bone Marrow Transplant 2011; 46: 257–261.

    Article  CAS  PubMed  Google Scholar 

  58. Sanz J, Montesinos P, Saavedra S, Lorenzo I, Senent L, Planelles D et al. Single-unit umbilical cord blood transplantation from unrelated donors in adult patients with chronic myelogenous leukemia. Biol Blood Marrow Transplant 2010; 16: 1589–1595.

    Article  PubMed  Google Scholar 

  59. Robin M, Sanz GF, Ionescu I, Rio B, Sirvent A, Renaud M et al. Unrelated cord blood transplantation in adults with myelodysplasia or secondary acute myeloblastic leukemia: a survey on behalf of Eurocord and CLWP of EBMT. Leukemia 2011; 25: 75–81.

    Article  CAS  PubMed  Google Scholar 

  60. Rodrigues CA, Sanz G, Brunstein CG, Sanz J, Wagner JE, Renaud M et al. Analysis of risk factors for outcomes after unrelated cord blood transplantation in adults with lymphoid malignancies: a study by the Eurocord-Netcord and lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol 2009; 27: 256–263.

    Article  PubMed  Google Scholar 

  61. Boissel N, Auclerc MF, Lheritier V, Perel Y, Thomas X, Leblanc T et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol 2003; 21: 774–780.

    Article  PubMed  Google Scholar 

  62. Ribera JM, Oriol A, Sanz MA, Tormo M, Fernandez-Abellan P, del Potro E et al. Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Espanol de Tratamiento en Hematologia pediatric-based protocol ALL-96. J Clin Oncol 2008; 26: 1843–1849.

    Article  CAS  PubMed  Google Scholar 

  63. Stock W, La M, Sanford B, Bloomfield CD, Vardiman JW, Gaynon P et al. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children’s Cancer Group and Cancer and Leukemia Group B studies. Blood 2008; 112: 1646–1654.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Huguet F, Leguay T, Raffoux E, Thomas X, Beldjord K, Delabesse E et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. J Clin Oncol 2009; 27: 911–918.

    Article  CAS  PubMed  Google Scholar 

  65. Nachman JB, La MK, Hunger SP, Heerema NA, Gaynon PS, Hastings C et al. Young adults with acute lymphoblastic leukemia have an excellent outcome with chemotherapy alone and benefit from intensive postinduction treatment: a report from the children’s oncology group. J Clin Oncol 2009; 27: 5189–5194.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Bassan R, Hoelzer D . Modern therapy of acute lymphoblastic leukemia. J Clin Oncol 2011; 29: 532–543.

    Article  PubMed  Google Scholar 

  67. Nishiwaki S, Miyamura K . Allogeneic stem cell transplant for adult Philadelphia chromosome-negative acute lymphoblastic leukemia. Leuk Lymphoma 2012; 53: 550–556.

    Article  PubMed  Google Scholar 

  68. Barrett AJ, Savani BN . Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents. Leukemia 2006; 20: 1661–1672.

    Article  CAS  PubMed  Google Scholar 

  69. Cho BS, Lee S, Kim YJ, Chung NG, Eom KS, Kim HJ et al. Reduced-intensity conditioning allogeneic stem cell transplantation is a potential therapeutic approach for adults with high-risk acute lymphoblastic leukemia in remission: results of a prospective phase 2 study. Leukemia 2009; 23: 1763–1770.

    Article  CAS  PubMed  Google Scholar 

  70. Stein AS, Palmer JM, O'Donnell MR, Kogut NM, Spielberger RT, Slovak ML et al. Reduced-intensity conditioning followed by peripheral blood stem cell transplantation for adult patients with high-risk acute lymphoblastic leukemia. Biol Blood Marrow Transplant 2009; 15: 1407–1414.

    Article  PubMed  PubMed Central  Google Scholar 

  71. Marks DI, Wang T, Perez WS, Antin JH, Copelan E, Gale RP et al. The outcome of full intensity and reduced intensity conditioning matched sibling or unrelated donor (URD) transplantation in adults with Philadelphia chromosome negative acute lymphoblastic leukemia (PH- ALL) in first and second complete remission (CR1 and CR2). Blood 2010; 116: 366–374.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Mohty M, Labopin M, Volin L, Gratwohl A, Socie G, Esteve J et al. Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation. Blood 2010; 116: 4439–4443.

    Article  CAS  PubMed  Google Scholar 

  73. Chessells JM, Hall E, Prentice HG, Durrant J, Bailey CC, Richards SM . The impact of age on outcome in lymphoblastic leukaemia; MRC UKALL X and XA compared: a report from the MRC Paediatric and Adult Working Parties. Leukemia 1998; 12: 463–473.

    Article  CAS  PubMed  Google Scholar 

  74. Rocha V, Mohty M, Gluckman E, Rio B . Reduced-intensity conditioning regimens before unrelated cord blood transplantation in adults with acute leukaemia and other haematological malignancies. Curr Opin Oncol 2009; 21 (Suppl 1): S31–S34.

    Article  PubMed  Google Scholar 

  75. Brunstein CG, Eapen M, Ahn KW, Appelbaum FR, Ballen KK, Champlin RE et al. Reduced-intensity conditioning transplantation in acute leukemia: the effect of source of unrelated donor stem cells on outcomes. Blood 2012; 119: 5591–5598.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Sebban C, Lepage E, Vernant JP, Gluckman E, Attal M, Reiffers J et al. Allogeneic bone marrow transplantation in adult acute lymphoblastic leukemia in first complete remission: a comparative study. French Group of Therapy of Adult Acute Lymphoblastic Leukemia. J Clin Oncol 1994; 12: 2580–2587.

    Article  CAS  PubMed  Google Scholar 

  77. Hunault M, Harousseau JL, Delain M, Truchan-Graczyk M, Cahn JY, Witz F et al. Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial. Blood 2004; 104: 3028–3037.

    Article  CAS  PubMed  Google Scholar 

  78. Ribera JM, Oriol A, Bethencourt C, Parody R, Hernandez-Rivas JM, Moreno MJ et al. Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial. Haematologica 2005; 90: 1346–1356.

    CAS  PubMed  Google Scholar 

  79. Pullarkat V, Slovak ML, Kopecky KJ, Forman SJ, Appelbaum FR . Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study. Blood 2008; 111: 2563–2572.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Cornelissen JJ, van der Holt B, Verhoef GE, van’t Veer MB, van Oers MH, Schouten HC et al. Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison. Blood 2009; 113: 1375–1382.

    Article  CAS  PubMed  Google Scholar 

  81. Ferra C, Sanz J, de la Camara R, Sanz G, Bermudez A, Valcarcel D et al. Unrelated transplantation for poor-prognosis adult acute lymphoblastic leukemia: long-term outcome analysis and study of the impact of hematopoietic graft source. Biol Blood Marrow Transplant 2010; 16: 957–966.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

This study was supported, in part, by a Japan Leukemia Research Fund grant, a Grant-in-Aid from the Ministry of Health, Labor and Welfare of Japan, and a Japanese Grant-in-Aid for Scientific Research.

Author information

Authors and Affiliations

  1. Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan

    S Nishiwaki

  2. Department of HSCT Data Management/Biostatistics, Nagoya University Graduate School of Medicine, Nagoya, Japan

    Y Atsuta

  3. Department of Hematology and Oncology, Hokkaido University Graduate School of Medicine, Sapporo, Japan

    J Tanaka

Authors
  1. S Nishiwaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Y Atsuta
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J Tanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S Nishiwaki.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nishiwaki, S., Atsuta, Y. & Tanaka, J. Allogeneic hematopoietic cell transplantation from alternative sources for adult Philadelphia chromosome-negative ALL: what should we choose when no HLA-matched related donor is available?. Bone Marrow Transplant 48, 1369–1376 (2013). https://doi.org/10.1038/bmt.2013.20

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2013.20

Keywords

This article is cited by

Search

Advanced search

Quick links